skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes

Review

(2335) Views  (591) Full article downloads

Authors: Karen Barnard, Mary Elizabeth Cox, Jennifer B Green

Published Date October 2010 Volume 2010:3 Pages 363 - 372
DOI: http://dx.doi.org/10.2147/DMSO.S10195

Karen Barnard1,2, Mary Elizabeth Cox1, Jennifer B Green1,2
1Department of Medicine, Division of Endocrinology, Diabetes, Metabolism and Nutrition, Duke University Medical Center, Durham, NC, USA; 2Department of Medicine, Division of Endocrinology, Durham Veterans Affairs Medical Center, Durham, NC, USA

Abstract: Adequate glycemic control in type 2 diabetes remains a difficult but achievable goal. The development of new classes of glucose-lowering medications, including in particular the incretin-based therapies, provides an opportunity to utilize combinations of medications which target multiple physiologic abnormalities in type 2 diabetes. Complementary combination therapy with sitagliptin–metformin lowers glucose via enhancement of insulin secretion, suppression of glucagon secretion, and insulin sensitization. Use of this combination in diabetes management will provide a greater degree of glycosylated hemoglobin-lowering than that seen with the use of either drug as monotherapy, is unlikely to cause significant hypoglycemia, and is generally associated with weight loss. The effectiveness, tolerability, and potential cost savings associated with the use of sitagliptin–metformin combination therapy make this an attractive option in diabetes management. The possible beneficial effects of this therapy on beta cell function, as well as its cardiovascular impact, remain inadequately explored but are of significant interest.

Keywords: diabetes mellitus, sitagliptin, dipeptidyl peptidase-4, combination therapy




 

Other articles by Dr Jennifer Green



Readers of this article also read:

Current concepts in targeted therapies for the pathophysiology of diabetic microvascular complications
Sitagliptin as combination therapy in the treatment of type 2 diabetes mellitus
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulin
Aerobic training increases skin perfusion by a nitric oxide mechanism in type 2 diabetes
The economic impact of obesity in the United States
Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes
Lixisenatide: evidence for its potential use in the treatment of type 2 diabetes
Insulin detemir for the treatment of obese patients with type 2 diabetes
Randomized, double-blind, placebo-controlled, linear dose, crossover study to evaluate the efficacy and safety of a green coffee bean extract in overweight subjects
  • Testimonials

    "You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio